Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia

Manoj M. Lalu, T. Csont, Richard Schulz

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective: To investigate whether myocardial and plasma matrix metalloproteinase (MMP) activities are altered during endotoxemia. Design: Prospective randomized, animal study. Setting: University research laboratory. Subjects: Male Sprague-Dawley rals, 250-300 g. Interventions: Rats were administered either bacterial lipopolysacctoride (LPS) or vehicle (pyrogen-free water). Groups of LPS-administered animals were killed at 0.5, 1, 3, 6, 12, and 24 hrs postinjection. Vehicle injected animals were killed at 6 hrs. Blood pressure was recorded before kill. Heart and plasma samples were analyzed by gelatin zymography and immunoblot. Measurement and Main Results: Blood pressure was significantly depressed at 3-24 hrs post-LPS injection; however, overt symptoms of endotoxemia and reduction in blood pressure were most significant 8-12 hrs posf-LPS. Heart samples from control rats revealed MMP-2 activity but no MMP-9 activity. MMP-2 activity was significantly depressed when overt symptoms of endotoxemia peaked at 8-12 hrs. Plasma MMP-2 activity significantly decreased 3-12 hrs after LPS injection. This loss of activity was associated with a loss of MMP-2 protein. In contrast, plasma MMP-9 activities were rapidly elevated following LPS injection, peaking between 1 and 12 hrs. MMP-9 activity correlated inversely with blood pressure. Conclusions: Endotoxemia induced rapid changes in MMP activity in both the myocardium and plasma. An increase in circulating MMP-9 activity may contribute to endotoxemic cardiovascular dysfunction.

Original languageEnglish
Pages (from-to)1332-1337
Number of pages6
JournalCritical Care Medicine
Volume32
Issue number6
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Endotoxemia
Matrix Metalloproteinases
Matrix Metalloproteinase 9
Matrix Metalloproteinase 2
Blood Pressure
Injections
Pyrogens
Gelatin
Myocardium
Water
Research
Proteins

Keywords

  • Endotoxemia
  • Matrix metalloproteinases
  • Myocardium
  • Plasma

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia. / Lalu, Manoj M.; Csont, T.; Schulz, Richard.

In: Critical Care Medicine, Vol. 32, No. 6, 06.2004, p. 1332-1337.

Research output: Contribution to journalArticle

@article{3a31f216e6024d0da3b3d33081786107,
title = "Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia",
abstract = "Objective: To investigate whether myocardial and plasma matrix metalloproteinase (MMP) activities are altered during endotoxemia. Design: Prospective randomized, animal study. Setting: University research laboratory. Subjects: Male Sprague-Dawley rals, 250-300 g. Interventions: Rats were administered either bacterial lipopolysacctoride (LPS) or vehicle (pyrogen-free water). Groups of LPS-administered animals were killed at 0.5, 1, 3, 6, 12, and 24 hrs postinjection. Vehicle injected animals were killed at 6 hrs. Blood pressure was recorded before kill. Heart and plasma samples were analyzed by gelatin zymography and immunoblot. Measurement and Main Results: Blood pressure was significantly depressed at 3-24 hrs post-LPS injection; however, overt symptoms of endotoxemia and reduction in blood pressure were most significant 8-12 hrs posf-LPS. Heart samples from control rats revealed MMP-2 activity but no MMP-9 activity. MMP-2 activity was significantly depressed when overt symptoms of endotoxemia peaked at 8-12 hrs. Plasma MMP-2 activity significantly decreased 3-12 hrs after LPS injection. This loss of activity was associated with a loss of MMP-2 protein. In contrast, plasma MMP-9 activities were rapidly elevated following LPS injection, peaking between 1 and 12 hrs. MMP-9 activity correlated inversely with blood pressure. Conclusions: Endotoxemia induced rapid changes in MMP activity in both the myocardium and plasma. An increase in circulating MMP-9 activity may contribute to endotoxemic cardiovascular dysfunction.",
keywords = "Endotoxemia, Matrix metalloproteinases, Myocardium, Plasma",
author = "Lalu, {Manoj M.} and T. Csont and Richard Schulz",
year = "2004",
month = "6",
doi = "10.1097/01.CCM.0000127778.16609.EC",
language = "English",
volume = "32",
pages = "1332--1337",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia

AU - Lalu, Manoj M.

AU - Csont, T.

AU - Schulz, Richard

PY - 2004/6

Y1 - 2004/6

N2 - Objective: To investigate whether myocardial and plasma matrix metalloproteinase (MMP) activities are altered during endotoxemia. Design: Prospective randomized, animal study. Setting: University research laboratory. Subjects: Male Sprague-Dawley rals, 250-300 g. Interventions: Rats were administered either bacterial lipopolysacctoride (LPS) or vehicle (pyrogen-free water). Groups of LPS-administered animals were killed at 0.5, 1, 3, 6, 12, and 24 hrs postinjection. Vehicle injected animals were killed at 6 hrs. Blood pressure was recorded before kill. Heart and plasma samples were analyzed by gelatin zymography and immunoblot. Measurement and Main Results: Blood pressure was significantly depressed at 3-24 hrs post-LPS injection; however, overt symptoms of endotoxemia and reduction in blood pressure were most significant 8-12 hrs posf-LPS. Heart samples from control rats revealed MMP-2 activity but no MMP-9 activity. MMP-2 activity was significantly depressed when overt symptoms of endotoxemia peaked at 8-12 hrs. Plasma MMP-2 activity significantly decreased 3-12 hrs after LPS injection. This loss of activity was associated with a loss of MMP-2 protein. In contrast, plasma MMP-9 activities were rapidly elevated following LPS injection, peaking between 1 and 12 hrs. MMP-9 activity correlated inversely with blood pressure. Conclusions: Endotoxemia induced rapid changes in MMP activity in both the myocardium and plasma. An increase in circulating MMP-9 activity may contribute to endotoxemic cardiovascular dysfunction.

AB - Objective: To investigate whether myocardial and plasma matrix metalloproteinase (MMP) activities are altered during endotoxemia. Design: Prospective randomized, animal study. Setting: University research laboratory. Subjects: Male Sprague-Dawley rals, 250-300 g. Interventions: Rats were administered either bacterial lipopolysacctoride (LPS) or vehicle (pyrogen-free water). Groups of LPS-administered animals were killed at 0.5, 1, 3, 6, 12, and 24 hrs postinjection. Vehicle injected animals were killed at 6 hrs. Blood pressure was recorded before kill. Heart and plasma samples were analyzed by gelatin zymography and immunoblot. Measurement and Main Results: Blood pressure was significantly depressed at 3-24 hrs post-LPS injection; however, overt symptoms of endotoxemia and reduction in blood pressure were most significant 8-12 hrs posf-LPS. Heart samples from control rats revealed MMP-2 activity but no MMP-9 activity. MMP-2 activity was significantly depressed when overt symptoms of endotoxemia peaked at 8-12 hrs. Plasma MMP-2 activity significantly decreased 3-12 hrs after LPS injection. This loss of activity was associated with a loss of MMP-2 protein. In contrast, plasma MMP-9 activities were rapidly elevated following LPS injection, peaking between 1 and 12 hrs. MMP-9 activity correlated inversely with blood pressure. Conclusions: Endotoxemia induced rapid changes in MMP activity in both the myocardium and plasma. An increase in circulating MMP-9 activity may contribute to endotoxemic cardiovascular dysfunction.

KW - Endotoxemia

KW - Matrix metalloproteinases

KW - Myocardium

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=2942528804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942528804&partnerID=8YFLogxK

U2 - 10.1097/01.CCM.0000127778.16609.EC

DO - 10.1097/01.CCM.0000127778.16609.EC

M3 - Article

C2 - 15187516

AN - SCOPUS:2942528804

VL - 32

SP - 1332

EP - 1337

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 6

ER -